Displaying 361 - 380 of 853
| Active Ingredient | OXCARBAZEPINE |
| Therapeutic Class | ANTICONVULSANTS MISCELLANEOUS |
| Indications | Monotherapy or adjunctive therapy in treatment of partial seizures . |
| Caution | As for Carbamazepine. A lower incidence of skin rashes but more pronounced hyponatremia than with carbamazepine have been reported. |
| Dose Range | Adult: 600 mg in 2 divided doses, increased, if necessary, in maximum increments of 600 mg at weekly intervals until the desired effect has been achieved. Maintenance dose: 600mg - 1200mg. Initial dose should be halved in patients with renal impairmen |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | PREGABALIN |
| Therapeutic Class | ANTICONVULSANTS MISCELLANEOUS |
| Indications | Peripheral and central neuropathic pain, adjunctive therapy for focal seizures with or without secondary generalization. |
| Caution | Dry mouth, constipation, vomiting, flatulence, oedema, dizziness, drowsiness, irritability, impaired attention, disturbances in muscle control and movement, speech disorder, impaired memory . |
| Dose Range |
Adult: Neuropathic pain: Initially 150 mg daily in 2-3 divided doses. Maximum dose 600mg daily in divided doses. Epilepsy: 150 mg daily increased after 1 week according to response 300 mg daily in 2-3 divided doses. Maximum dose 600mg daily in divided dos |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | SODIUM VALPROATE |
| Therapeutic Class | ANTICONVULSANTS MISCELLANEOUS |
| Indications | Grand mal, petit mal, myoclonic and temporal lobe seizures. |
| Caution |
Nausea, vomiting. Ataxia, increase in appetite and weight gain. C.f. Prescribing in liver disease p. 17. |
| Dose Range | Adult: i.v. inj over 3-5 minutes 10mg/kg followed by i.v infusion to a max.2.5g daily. Child 1 mth -12 yrs: Initially orally 5-7.5mg/kg twice daily, usual maintainence dose 12.5-15mg/kg twice daily . Child 12-18 yrs: Initially 300mg twice daily i |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | SODIUM VALPROATE | VALPROIC ACID |
| Therapeutic Class | ANTICONVULSANTS MISCELLANEOUS |
| Indications | All types of epilepsy. Most suitable for patients needing high doses, on poly therapy or on multiple daily doses. |
| Caution | As for sodium valproate. |
| Dose Range |
Adult: Initially 600mg daily in two divided doses, increasing by 200mg daily at 3 day intervals to 1-2g or a maximum of 2.5g/day . Pediatric over 20kg: Initially 400mg/day in divided doses increasing to 20-30mg/kg daily or a maximum of 35mg/kg/day . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | TOPIRAMATE |
| Therapeutic Class | ANTICONVULSANTS MISCELLANEOUS |
| Indications | Lennox-Gastaut syndrome, migraine prohylaxis, partial seizure and tonic-clonic seizure as adjunct or monotherapy . |
| Caution | Anemia, increased body temperature, dyspnea, hepatitis, hypohidrosis, leucopenia, liver failure. |
| Dose Range |
Migraine prophylaxis: Initally 25mg at night to a usual dose of 50mg twice a day. Seizures: Initially 25 -50 mg at night for 1 week increased by increments of 25-50 mg at intervals of 1- 2 weeks to the usual maintenance dose for adjunctive therapy of 200 |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | VALPROIC ACID |
| Therapeutic Class | ANTICONVULSANTS MISCELLANEOUS |
| Indications | Grand mal, petit mal, myoclonic and temporal lobe seizures. |
| Caution | Do not chew capsules, swallow whole to avoid irritation of mouth and throat. If G.I. up set occurs it may be taken with food. Transient hair loss, thrombocytopenia, impaired liver function. |
| Dose Range | 250mg 2-3 times daily to a maximum of 2.5g daily . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | PSYCHOTHERAPEUTIC AGENTS |
| Therapeutic Class | PSYCHOTHERAPEUTIC AGENTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | MOCLOBEMIDE |
| Therapeutic Class | MONOAMINE OXIDASE INHIBITORS |
| Indications | Depression, social anxiety disorder. |
| Caution | Sleep disturbances, dizziness, agitation, feelings of anxiety , restlessness, irritability, headache. |
| Dose Range |
Adult: Depression: Initially 300 mg daily in divided doses, adjusted according to response; usual dose 150–600 mg daily after a meal.Anxiety: Initially 300 mg daily for 3 days, then increased to 600 mg daily in 2 divided doses continued for 8-12 weeks to |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | MONOAMINE OXIDASE INHIBITORS |
| Therapeutic Class | MONOAMINE OXIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | VENLAFAXINE |
| Therapeutic Class | SELECTIVE SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBI |
| Indications | Depression, social anxiety disorder and panic. |
| Caution | Nausea, headache, insomnia, somnolence, dry mouth, dizziness, constipation, sexual dysfunction, asthenia, sweating, and ervousness. |
| Dose Range |
Depression: Initial daily dose of venlafaxine 75 mg in two or three divided doses. Anxiety : 75 mg once daily. Panic Disorder: 37.5mg for 7 days increasing to 75mg daily |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | CITALOPRAM |
| Therapeutic Class | SELECTIVE SEROTONIN REUPTAKE INHIBITORS |
| Indications | Major depression, obsessive-compulsive disorder, panic disorder. |
| Caution | As for fluoxetine. |
| Dose Range | Initial dose of 20mg/day as a single dose, increase as required after one week to a maximum of 40mg/day . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | DESVENLAFAXINE |
| Therapeutic Class | SELECTIVE SEROTONIN REUPTAKE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ESCITALOPRAM |
| Therapeutic Class | SELECTIVE SEROTONIN REUPTAKE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | FLUOXETINE |
| Therapeutic Class | SELECTIVE SEROTONIN REUPTAKE INHIBITORS |
| Indications | Depression, obsessive compulsive disorder, bulimia nervosa, premenstrual dysphoric disorder. |
| Caution | The main side effect is nausea; other side effects are hypotension, CNS symptoms (headache, anxiety, nervousness, insomnia), dry mouth, anorexia and visual disturbances; weight loss (but not weight ga More ... |
| Dose Range | Usual effective dose for depression, obsessive compulsive disorder and premenstrual dysphoric disorder is 20mg/day in the morning; however, doses up to 80mg/day have been used. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | PAROXETINE |
| Therapeutic Class | SELECTIVE SEROTONIN REUPTAKE INHIBITORS |
| Indications | Major depression, obsessive-compulsive disorder, panic disorder. |
| Caution | As for fluoxetine. |
| Dose Range | Adult: 10-60mg daily. Maximum dose in the elderly 40mg daily . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | SERTRALINE |
| Therapeutic Class | SELECTIVE SEROTONIN REUPTAKE INHIBITORS |
| Indications |
Major depressive disorder, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, premenstrual dysphoric disorder and social phobia. |
| Caution | Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies with major depressive disorder (MDD) and other psychiatric disorde More ... |
| Dose Range |
Adult: 50 mg daily increased, if necessary, in increments of 50 mg at intervals of at least a week to a maximum of 200 mg daily. Child: Obsessive-compulsive disorder: children 6-12 yr, 25mg/day, 13-17 yr, 50mg/day orally as a single dose in the morning or |
| Drug Interactions | |
| Pregnancy | Category C |
| Breast Feeding |
| Active Ingredient | AMITRIPTYLINE |
| Therapeutic Class | TRICYCLICS & OTHER NOREPINEPHRINE REUPTAKE INHIBIT |
| Indications | Agitated depression. |
| Caution | Acute retention especially in prostatic hypertrophy. Tricyclics may antagonise the action of adrenergic neurone blocking drugs e.g. guanethidine, and may seriously impair their antihypertensive effec More ... |
| Dose Range | 50-200mg daily in divided doses. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | CLOMIPRAMINE |
| Therapeutic Class | TRICYCLICS & OTHER NOREPINEPHRINE REUPTAKE INHIBIT |
| Indications | Most useful in obsessional and phobic disorders. |
| Caution | See amitriptyline hydrochloride. Weight gain, urinary retention, tremor. C.f. prescribing in liver disease. P. 12. |
| Dose Range |
Initially 25 mg daily (or 10 mg daily for elderly patients or those sensitive to tricyclics) increased gradually over two weeks to 100 to 150 mg daily . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | IMIPRAMINE |
| Therapeutic Class | TRICYCLICS & OTHER NOREPINEPHRINE REUPTAKE INHIBIT |
| Indications | Treatmment of juvenile enuresis. Depressive illness. |
| Caution | Causes less confusion in the elderly. c.f. prescribing in liver disease p.14. See amitripty line. |
| Dose Range |
Adult: Initially up to 75mg in divided doses, gradually increasing to 150-200mg. In the elderly initial dose of 10mg daily increased gradullay to 30-50mg daily. Paediatric: 6-7 yrs 25 mg 8-11 yrs 25- 50mg, 11-18yrs 50-75mg at bedtime innocturnal enuresis |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | AGOMELATINE |
| Therapeutic Class | ANTIDEPRESSANTS MISCELLANEOUS |
| Indications | Major depression. |
| Caution |
Bipolar disorder; diabetes; excessive alcohol consumption: Abdominal pain; agitation; anxiety ; back pain; constipation. |
| Dose Range |
25 mg at bedtime, increased if necessary after 2 weeks, to 50 mg daily . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |